688192 迪哲医药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-47.301-84.976-34.871-37.827-76.720
总资产报酬率 ROA (%)-21.949-61.913-30.491-34.110-64.841
投入资产回报率 ROIC (%)-26.963-71.379-33.498-36.913-76.716

边际利润分析
销售毛利率 (%)97.65696.478--12.42012.471
营业利润率 (%)-212.379-1,213.308---6,512.850-2,112.991
息税前利润/营业总收入 (%)-207.642-1,207.359---6,441.487-2,014.226
净利润/营业总收入 (%)-212.379-1,213.419---6,512.850-2,113.094

收益指标分析
经营活动净收益/利润总额(%)108.813104.851106.708101.841134.946
价值变动净收益/利润总额(%)-1.705-2.033-5.730-0.353-0.452
营业外收支净额/利润总额(%)0.0000.0000.0000.0000.000

偿债能力分析
流动比率 (X)1.8712.0305.9289.9646.062
速动比率 (X)1.8121.9785.9089.9646.062
资产负债率 (%)62.21743.28815.53510.3048.723
带息债务/全部投入资本 (%)48.90727.8060.5610.6600.000
股东权益/带息债务 (%)96.002242.22217,006.87214,625.948--
股东权益/负债合计 (%)59.510131.011543.703870.5371,046.410
利息保障倍数 (X)-43.839-202.96590.190-90.264-20.394

营运能力分析
应收账款周转天数 (天)62.673189.449--252.938109.306
存货周转天数 (天)1,058.0851,597.977--0.0000.000